NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

A first-in-class therapy received approval, supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trial results showing significant LDL-C reductions and favorable tolerability. The approval is a meaningful commercial and clinical catalyst for the developer, potentially improving its competitive position in cholesterol-lowering treatment.